Skip to main navigation Skip to search Skip to main content

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.

Translated title of the contribution: Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
  • E. Vellenga
  • , W.L.J. van Putten
  • , M.B. van 't Veer
  • , J.M. Zijlstra
  • , W.E. Fibbe
  • , M.H.J. van Oers
  • , L.F. Verdonck
  • , P.W. Wijermans
  • , G.W. van Imhoff
  • , P.J. Lugtenburg
  • , P.C. Huijgens

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionRituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
Original languageUndefined/Unknown
Pages (from-to)537-543
Number of pages7
JournalBlood
Volume111
Issue number2
Publication statusPublished - 2008

Cite this